| Company/Division name | Piramal Pharma Solutions |
| Parent company | Piramal Pharma Ltd. |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2026 |
| Year reshoring implemented or to be implemented: | 2028 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 85 |
| City reshored to: | Lexington |
| State(s) reshored to: | KY |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Cyclophosphamide, oncology drug |
| What non-domestic negative factors made offshoring less attractive? | Strained offshore relationships, Supply chain interruption |
| What domestic positive factors made reshoring more attractive? | Better Control of Process/Delivery/Factory, Geopolitical Risk, Impact on domestic economy, Lead time/Time to market, Proximity to customers/market |
